Table 4.
Anti-Tetanus Toxoid Antibody Concentrations (μg/mL) at 6 Months of Life
| LRTI+ | LRTI− | ||||||
|---|---|---|---|---|---|---|---|
| No. of vaccine doses | N | GMC | 95% CI | N | GMC | 95% CI | p |
| 0 | 5 | 0.1 | 0.02–0.3 | 15 | 0.1 | 0.03–0.3 | .97 |
| 1 | 28 | 0.1 | 0.04–0.1 | 29 | 0.1 | 0.03–0.1 | |
| 2 | 49 | 0.4 | 0.3–0.7 | 73 | 0.5 | 0.4–0.8 | .50 |
| 3 | 1 | 0.4 | — | 2 | 1.3 | — | |
| 4 | 1 | 1.1 | — | 0 | — | — | — |
To adjust for one-to-n matching, p values were calculated by linear mixed-effects models; p values for the comparison of LRTI+ to LRTI− were determined combining no. of vaccine doses of 0 and 1 and also for combining 2 and 3 doses.